RT Journal Article
SR Electronic
T1 NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: A randomized prospective phase 2 trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.11.22278658
DO 10.1101/2022.08.11.22278658
A1 Nierenberg, Andrew
A1 Lavin, Philip
A1 Javitt, Daniel C.
A1 Shelton, Richard
A1 Matthew, Sanjay
A1 Besthof, Robert A
A1 Javitt, Jonathan C.
YR 2022
UL http://medrxiv.org/content/early/2022/08/12/2022.08.11.22278658.abstract
AB Objectives We tested the hypothesis that after initial improvement with intravenous ketamine in patients with bipolar disorder (BD) with severe depression and acute suicidal thinking or behavior, a fixed-dose combination of oral D-cycloserine (DCS) and lurasidone (NRX-101) can maintain improvement more effectively lurasidone alone.Methods This was a multi-center, double-blind, two-stage, parallel randomized trial. Adult BD patients with depression and suicidal ideation or behavior were infused with ketamine or saline (Stage 1); those who improved were randomized to a fixed dose combination of DCS and lurasidone vs. lurasidone alone (Stage 2) to maintain the improvement achieved in Stage 1. Depression was measured by the Montgomery Åsberg Depression Rating Scale (MADRS) and suicidal thinking and behavior was measured by the Columbia Suicide Severity Rating Scale (C-SSRS); global improvement was measured by the clinical global severity scale (CGI-S).Results Thirty-seven patients were screened and 22 were enrolled, randomized, and treated. All 22 patients treated in Stage 1 (17 with ketamine and 5 with saline) were enrolled into Stage 2 and 11 completed the study. The fixed dose combination of DCS and lurasidone was significantly more effective than lurasidone alone in maintaining improvement in depression (MADRS LMS Δ-7.7; p=.03) and reducing suicidal ideation, as measured by C-SSRS (Δ-1.5; p=0.02) and by CGI-SS (Δ-2.9; p=0.03), and with a non-statistically significant decrease in depressive relapse (0% vs. 40%; p=0.07). This sequential treatment regimen did not cause any significant safety events and demonstrated improvements in patient reported side effects.Conclusions Sequential treatment of a single infusion of ketamine followed by NRX-101 maintenance is a promising therapeutic approach for reducing depression and suicidal ideation in patients with bipolar depression who require hospitalization due to acute suicidal ideation and behavior. On the basis of these findings, Breakthrough Therapy Designation was awarded and a Special Protocol Agreement was granted by the FDA for a registrational trial.Competing Interest StatementDCJ,JCJ, RBE receive compensation from and have equity interest in NRx Pharmaceuticals, Inc. Lavin Statistical Associates is paid for independent statistical analysis by NRx Pharmaceuticals, Inc.Clinical Trialwww.clinicaltrials.gov NCT 02974010Clinical Protocols https://clinicaltrials.gov/ProvidedDocs/10/NCT02974010/Prot_SAP_000.pdf Funding StatementThis study was funded by NRx Pharmaceuticals, Inc. (Wilmington, DE)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Advarra IRB (Cincinnati, OH) gave ethical approval for this work. Approval Number: 201704604 The research was conducted under an IND 129194 granted by the US FDA. The study was under the supervision of an independent Data Safety Monitoring Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://clinicaltrials.gov/ct2/show/results/NCT02974010